- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
March 12, 2024 updated by: Massive Bio, Inc.
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Study Overview
Status
Recruiting
Conditions
- Melanoma
- Follicular Lymphoma
- Carcinoma
- Myelodysplastic Syndromes
- Leukemia
- Cancer
- Breast Cancer
- Myeloproliferative Disorders
- Glioblastoma
- Myelofibrosis
- Ovarian Cancer
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Neuroendocrine Tumors
- Non Small Cell Lung Cancer
- COVID
- Non Hodgkin Lymphoma
- Cholangiocarcinoma
- Bladder Cancer
- Endometrial Cancer
- Urothelial Carcinoma
- Cancer of Liver
- Cancer, Breast
- Myeloproliferative Neoplasm
- Cancer of Pancreas
- Cancer of Stomach
- Cancer of Cervix
- Central Nervous System Tumor
- Cancer of Colon
- Testicular Cancer
- Cancer, Advanced
- Cancer of Rectum
- Mismatch Repair Deficiency
- Cancer, Lung
- BRCA Gene Rearrangement
- Cancer of Skin
- Cancer of Esophagus
- Cancer Liver
- Cancer, Metastatic
- Cancer Prostate
- Cancer of Kidney
- Cancer of Neck
- Cancer of Larynx
Intervention / Treatment
Detailed Description
The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT.
Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
Patients voluntarily enroll into the registry, which is non-interventional with no protocol-mandated tests/procedures - all treatment decisions are made at the discretion of PP in consultation with their pts, based on the AI CT matching report, and VTB support.
CTE will be assessed on variables including biomarkers, barriers to enrollment.
Study duration anticipated as ~36 mo (~24-mo enrollment followed by 12 mo of data collection, to occur every 3 mo).
The primary analysis will be performed 12 mo after last pt enrolled.
The impact time to initiation of CTE on PFS and OS will be estimated by Kaplan-Meier and Cox multivariable survival analysis.
Enrollment is ongoing, with a target of ≥50,000 patients.
Study Type
Observational
Enrollment (Estimated)
50000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Selin Kurnaz, PhD
- Phone Number: +1(917) 336-3319
- Email: skurnaz@massivebio.com
Study Contact Backup
- Name: Amanda Huttis, RN
- Phone Number: +1(917) 336-3319
- Email: ahuttis@massivebio.com
Study Locations
-
-
New York
-
New York, New York, United States, 10006
- Recruiting
- Massive Bio, Inc
-
Contact:
- Amanda Huttis, RN
- Phone Number: 844-627-7246
- Email: support@massivebio.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider clinical trial enrollment (CTE) has already been made by their primary providers (PP).
Description
Inclusion Criteria:
- Pts with solid and hematological malignancies;
- Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform
- Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
Exclusion Criteria:
- ECOG PS > 2;
- Abnormal organ function;
- Hospice enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study Group
Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
|
Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT.
Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients Eligible for CTE versus Actual CTE
Time Frame: Through study completion, an average of 1 year
|
CTE Accrual
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis
Time Frame: 4 years
|
OS
|
4 years
|
Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis
Time Frame: 4 years
|
PFS
|
4 years
|
Identification of Barriers to CTE
Time Frame: Through study completion, an average of 1 year
|
To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
|
Through study completion, an average of 1 year
|
Real World Data Analytics
Time Frame: Through study completion, an average of 1 year
|
To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
|
Through study completion, an average of 1 year
|
Virtual Tumor Board Utilization
Time Frame: Through study completion, an average of 1 year
|
VTB Use Rate
|
Through study completion, an average of 1 year
|
Time from Intervention to Actual CTE (months)
Time Frame: Through study completion, an average of 1 year
|
Time to CTE
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Selin Kurnaz, PhD, Massive Bio, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2018
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
February 13, 2018
First Submitted That Met QC Criteria
February 24, 2018
First Posted (Actual)
March 2, 2018
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Nervous System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Endocrine System Diseases
- Gonadal Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Breast Diseases
- Liver Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Otorhinolaryngologic Neoplasms
- Otorhinolaryngologic Diseases
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Esophageal Diseases
- Colorectal Neoplasms
- Pancreatic Diseases
- Laryngeal Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Lymphoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Myelodysplastic Syndromes
- Stomach Neoplasms
- Testicular Neoplasms
- Breast Neoplasms
- Head and Neck Neoplasms
- Lung Neoplasms
- Carcinoma
- Glioblastoma
- Rectal Neoplasms
- Endometrial Neoplasms
- Lymphoma, Mantle-Cell
- Pancreatic Neoplasms
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Cholangiocarcinoma
- Liver Neoplasms
- Skin Neoplasms
- Esophageal Neoplasms
- Colonic Neoplasms
- Neuroendocrine Tumors
- Myeloproliferative Disorders
- Laryngeal Neoplasms
Other Study ID Numbers
- SYNERGY-AI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
Clinical Trials on Clinical Trial Matching
-
Luzerner KantonsspitalCompletedRetinal Disease | Eye DiseaseSwitzerland
-
The University of Texas Health Science Center at...Genentech, Inc.RecruitingEducational ProblemsUnited States
-
Aymara Abreu CorralesUniversity of SalamancaNot yet recruitingMultiple Sclerosis
-
Lawson Health Research InstituteLondon Health Sciences CentreCompleted
-
University of CincinnatiAmerican Heart AssociationCompleted
-
Universitas Sumatera UtaraCompletedNutrient DeficiencyIndonesia
-
University of AarhusRecruitingHead and Neck NeoplasmsDenmark
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerCompleted
-
Ain Shams UniversityUnknownBreast Cancer | Clinical TrialsEgypt
-
Lantheus Medical ImagingWithdrawn